Suren Ajjarapu (TRxADE Health)
July 20, 2021 07:20 AM EDT
Financing

The next SPAC is here, com­ing from a phar­ma e-com­merce CEO, as a Flori­da biotech prices at the low end

Max Gelman

Senior Editor

The newest health­care blank-check com­pa­ny has ar­rived, com­ing from the CEO of a com­pa­ny that is at­tempt­ing to shake up the dig­i­tal phar­ma­ceu­ti­cal space. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

A service from the Financial Times